China pits humanoid robots against humans in half-marathon
By Eduardo Baptista and Alessandro Diviggiano
BEIJING (Reuters) -Twenty-one humanoid robots joined thousands of runners at the Yizhuang half-marathon in Beijing on Saturday, the first time these machines have raced alongside humans over a 21-km (13-mile) course.
The robots from Chinese manufacturers such as DroidVP and Noetix Robotics came in all shapes and sizes, some shorter than 120 cm (3.9 ft), others as tall as 1.8 m (5.9 ft). One company boasted that its robot looked almost human, with feminine features and the ability to wink and smile.
Some firms tested their robots for weeks before the race. Beijing officials have described the event as more akin to a race car competition, given the need for engineering and navigation teams.
"The robots are running very well, very stable ... I feel I'm witnessing the evolution of robots and AI,' said spectator He Sishu, who works in artificial intelligence.
The robots were accompanied by human trainers, some of whom had to physically support the machines during the race.
A few of the robots wore running shoes, with one donning boxing gloves and another wearing a red headband with the words "Bound to Win" in Chinese.
The winning robot was Tiangong Ultra, from the Beijing Innovation Center of Human Robotics, with a time of 2 hours and 40 minutes. The men's winner of the race had a time of 1 hour and 2 minutes.
The centre is 43% owned by two state-owned enterprises, while tech giant Xiaomi's robotics arm and leading Chinese humanoid robot firm UBTech have equal share in the rest.
Tang Jian, chief technology officer for the robotics centre, said Tiangong Ultra's performance was aided by long legs and an algorithm allowing it to imitate how humans run a marathon.
"I don't want to boast but I think no other robotics firms in the West have matched Tiangong's sporting achievements," Tang said, adding that the robot switched batteries just three times during the race.
SOME ROBOTS STRUGGLE
Some robots, like Tiangong Ultra, completed the race, while others struggled from the beginning. One robot fell at the starting line and lay flat for a few minutes before getting up and taking off. One crashed into a railing after running a few metres, causing its human operator to fall over.
Although humanoid robots have made appearances at marathons in China over the past year, this is the first time they have raced alongside humans.
China is hoping that investment in frontier industries like robotics can help create new engines of economic growth. Some analysts, though, question whether having robots enter marathons is a reliable indicator of their industrial potential.
Alan Fern, professor of computer science, artificial intelligence and robotics at Oregon State University, said contrary to claims from Beijing officials that such a race requires "AI breakthroughs", the software enabling humanoid robots to run was developed and demonstrated more than five years ago.
"Chinese companies have really focused on showing off walking, running, dancing, and other feats of agility.
"Generally, these are interesting demonstrations, but they don't demonstrate much regarding the utility of useful work or any type of basic intelligence," Fern said.
Tang, the robotic centre's CTO, said: "A focus going forward for us will be industrial applications for humanoid robots so they can truly enter factories, business scenarios, and finally households."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Army surveillance balloons spotted over Tucson raise privacy concerns from advocates
An Aerostar high-altitude balloon as seen from the ground in Tucson. Photo by Dugan Meyer The U.S. Army and a private company are flying high-altitude surveillance balloons over the Tucson area, raising concerns among privacy advocates. Multiple high-altitude balloons have been spotted over the Tucson and Sierra Vista area for more than a week, with one balloon in particular staying over the area longer than any of the others. That balloon, with the registration number N257TH, has made headlines in the past. The balloon is owned by South Dakota aerospace company Aerostar, and in 2023 was mistaken for a Chinese spy balloon. The balloon is actually part of Aerostar's 'Thunderhead' balloon system, which has been doing multiple tests with the military and other contractors across the nation and around the globe. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX 'It is a technology that should not and constitutionally cannot be applied to the American people,' Jay Stanley, a senior policy analyst at the American Civil Liberties Union, told the Arizona Mirror. 'Even testing for eventual overseas use in legitimate combat theaters raises a lot of questions about what kind of data is being collected.' Aerostar would not answer specific questions about what type of testing was being done. The company referred additional questions to the U.S. Department of Defense and the Army, neither of which responded to multiple requests for comment. Aerostar confirmed that the flights were not connected to U.S. Customs and Border Patrol or Department of Homeland Security programs, 'however high-altitude balloons would be ideal for that type of mission,' Aerostar Culture and Communications Director Anastasia Quanbeck said in an email to the Mirror. 'By leveraging directional wind patterns at high altitudes, Aerostar's Thunderhead Balloon Systems offer groundbreaking capabilities for navigation and persistence over areas of interest,' she said. 'Aerostar Thunderhead Balloon Systems are capable of supporting intelligence, surveillance, and reconnaissance missions, as well as extending communications across wide distances, environmental monitoring, earth observation, and scientific research.' Quanbeck said she was not able to discuss the work the company does with the DOD or the Army. The 'Thunderhead' balloons are similar to 'spy balloons' that have made international headlines in recent years. They fly between 60,000 to 100,000 feet, twice the height of a commercial airliner, and can carry much larger payloads than a conventional drone or other small high altitude spy-planes. After Chinese spy-balloons made incursions into United States airspace in 2023, it was reported that the Army would begin pursuing a similar program to launch in 2025. Aerostar had previously been used in testing exercises. In the past, Aerostar has used blimps as surveillance systems. They were originally used for surveillance in combat zones overseas, then in 2012 were used along the border and still are often spotted at the border today. However, the systems that have been seen floating over southern Arizona in recent weeks have key differences from the blimps: they sit higher in the sky, are much larger, can stay afloat for much longer and can carry larger payloads. As reported by The War Zone, the Army has been researching using high-altitude balloons to deploy drone swarms into enemy territory far above the reach of enemy defenses. But the balloons over southern Arizona raise questions about privacy. In 2021, the 4th U.S. Circuit Court of Appeals ruled that the Baltimore Police Department's use of an aerial surveillance program that recorded virtually all of the city for 12 hours a day for six months was unconstitutional. Stanley thinks that case is pertinent when talking about what may be going on in Arizona. 'I think, if anything, it becomes more sensitive when the military is doing it,' Stanley said. Wide-area persistent surveillance or wide-area airborne surveillance is a technique that got its start in early days of the Iraq war but later would find itself in the hands of police. The technology has evolved from being very heavy but is now light enough to fit onto blimps and balloons. Aerostar and the military have not elaborated on what systems are aboard the balloons over the Tucson area, but Stanley said that systems like the ones Aerostar is developing could be used to deploy persistent surveillance systems, ultimately surveilling entire communities for days on end. The Thunderhead system boasts the ability to stay afloat for up to 30 days, and Aerostar has tested it along with its Zephyr platform, a new type of unmanned aircraft that also flies at high altitudes and has been tested in Arizona. That aircraft can stay in the air for up to two months. The balloon also could be carrying a variety of equipment, such as radar, lidar, GPS or cameras, Stanley said. While much of this equipment could be installed on a traditional aircraft, the balloon can stay afloat over an area at a higher altitude for longer durations, allowing for more persistent surveillance of an area, something that Stanley said can be a problem for everyday Americans. 'Following someone around for long periods of time reveals things about their life,' Stanley said. 'How often they go to the bar, associations, who they are hanging out with — and that is too much power for the government or anyone else to have over individuals.' SUPPORT: YOU MAKE OUR WORK POSSIBLE
Yahoo
41 minutes ago
- Yahoo
Britain pledges to deliver 100,000 drones to Ukraine by April 2026
LONDON (Reuters) -Britain pledged on Wednesday to supply 100,000 drones to Ukraine by the end of the current financial year in April 2026, marking a tenfold increase, after saying the unmanned aerial vehicles had transformed the way wars are fought. The government on Monday endorsed an independently-produced Strategic Defence Review, which calls for a more lethal, tech-driven army to counter emerging threats, including possible Russian aggression. Britain, one of Ukraine's staunchest Western supporters, plans to learn from Kyiv's more than three-year fight against Russian invasion, during which drones have transformed the battlefield. The 350-million-pound ($473 million) drone package is part of a broader 4.5-billion-pound military support initiative for Ukraine, the government said. Defence Secretary John Healey will make the announcement at a 50-nation Ukraine Defence Contact Group meeting in Brussels, co-hosted with Germany. "The UK is stepping up its support for Ukraine by delivering hundreds of thousands more drones this year and completing a major milestone in the delivery of critical artillery ammunition," Healey said in a statement ahead of the meeting. In addition to the drone deliveries, Britain said it has completed the shipment of 140,000 artillery shells to Ukraine since January and will spend a further 247 million pounds this year training Ukrainian troops. ($1 = 0.7402 pounds)
Boston Globe
an hour ago
- Boston Globe
From no hope to a potential cure for a deadly blood cancer
A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. And after five years, it still has not returned in those patients -- a result never before seen in this disease. Advertisement These results, in patients whose situation had seemed hopeless, has led some battle-worn American oncologists to dare to say the words 'potential cure.' Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr. Norman Sharpless, a former director of the National Cancer Institute who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.' The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which has an exclusive licensing agreement with Legend Biotech. The 36,000 Americans who develop multiple myeloma each year face an illness that eats away at bones, so it looks as if holes have been punched out in them, said Dr. Carl June, of the University of Pennsylvania. Bones collapse. June has seen patients who lost 6 inches in height. Advertisement 'It's a horrible, horrible death,' June said. 'Right now advanced myeloma is a death sentence.' (June has immunotherapy patents that are owned by his university.) There have been treatment advances that increased median survival from two years to 10 over the past two decades. But no cures. Dr. Peter Voorhees of the Atrium Health Levine Cancer Institute in North Carolina and the Wake Forest University School of Medicine, who is lead researcher for the newly published study, said patients usually go through treatment after treatment until, ultimately, the cancer prevails, developing resistance to every class of drug. They end up with nothing left to try. The Legend immunotherapy is a type known as CAR-T. It is delivered as an infusion of the patient's own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionized prospects for patients with other types of blood cancer, like leukemia. Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it can have severe side effects including a high fever, trouble breathing and infections. Patients can be hospitalized for weeks after receiving it. But Legend managed to develop one that works in multiple myeloma, defying skeptics. The Chinese company gained attention for its CAR-T eight years ago when it made extravagant claims, which were met by snickers from American researchers. Advertisement Johnson & Johnson, though, was looking for a CAR-T to call its own. So, said Mark Wildgust, an executive in the oncology section of the American drug giant, the company sent scientists and physicians to China to see if the claims were true. 'We went site by site to look at the results,' he said. The company was convinced. It initiated a collaboration with Legend and began testing the treatment in patients whose myeloma had overcome at least one standard treatment. Compared with patients who had standard treatment, those who had the immunotherapy lived longer without their disease progressing. The immunotherapy received regulatory approval in that limited setting and is sold under the brand name Carvykti. The study did not determine whether this difficult treatment saved lives. The new study took on a different challenge -- helping patients at the end of the line after years of treatments. Their immune systems were worn down. They were, as oncologists said, 'heavily pretreated.' So even though CAR-T is designed to spur their immune systems to fight their cancer, it was not clear their immune systems were up to it. Oncologists say that even though most patients did not clear their cancer, having a third who did was remarkable. To see what the expected life span would be for these patients without the immunotherapy, Johnson & Johnson looked at data from patients in a registry who were like the ones in its study -- they had failed every treatment. They lived about a year. For Anne Stovell of New York, one of the study patients whose cancer disappeared, the result is almost too good to be true. She says she went through nine drugs to control her cancer after it was diagnosed in 2010, some of which had horrendous side effects. Each eventually failed. Advertisement Taking the Legend CAR-T was difficult -- she said she had spent nearly three weeks in the hospital. But since that treatment six years ago, she has no sign of cancer. She said it was still difficult for her to believe her myeloma is gone. A new ache -- or an old one -- can bring on the fear. 'There's that little seed of doubt,' she said. But in test after test, the cancer has not reappeared. 'It's a relief for me every year to get a bone marrow biopsy,' she said. Myeloma experts applauded the results. Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are 'hideously expensive,' June said, costing more than $100,000 a year. The total cost over the years can be millions of dollars, June said, usually paid by insurers, 'and it doesn't even cure you.' CAR-T is expensive too. Carvykti's list price is $555,310. But it is a one-time treatment. And, more important, the hope is that perhaps by giving it earlier in the course of the disease, it could cure patients early on. Johnson & Johnson is now testing that idea. Dr. Kenneth Anderson, a myeloma expert at Dana-Farber Cancer Institute who was not involved with the study, said that if the treatment is used as a first-line treatment, 'cure is now our realistic expectation.' That, at least, is the hope, Sharpless said. And for those like the patients in the new study who are living at least five years -- so far -- without disease, the outcome 'really is eye-popping,' Sharpless said. Advertisement 'That's getting to a point where you wonder if it will ever come back,' he added. This article originally appeared in
